Insider · CIK 0001376854
Philippe Amouyal
Files at LXRX (LEXICON PHARMACEUTICALS, INC.), CAVA (CAVA GROUP, INC.). First filing -, latest -.
Philippe Amouyal files SEC Form 4 as director at LXRX (LEXICON PHARMACEUTICALS, INC.), and also at CAVA (CAVA GROUP, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Philippe Amouyal has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | CAVA CAVA GROUP, INC. | AGrant or award Common Stock | +1,881 | $0.00 | $0 | 19,955 | Jun 24, 2026 |
| Jun 3, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 374,486 | Jun 4, 2026 |
| Jun 3, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| Jun 20, 2025 | CAVA CAVA GROUP, INC. | AGrant or award Common Stock | +1,767 | $0.00 | $0 | 18,074 | Jun 24, 2025 |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +103,806 | $0.00 | $0 | 103,806 | Jun 3, 2025 |
| Jun 3, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +89,312 | $0.00 | $0 | 89,312 | Jun 3, 2025 |
| May 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +36,810 | $0.00 | $0 | 285,174 | May 13, 2025 |
| May 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -36,810 | $0.00 | $0 | 0 | May 13, 2025 |
Questions about Philippe Amouyal
Answered from the filings on this page, as of the latest one.
Is Philippe Amouyal buying or selling?
Philippe Amouyal has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Philippe Amouyal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Philippe Amouyal has 0.
Where does Philippe Amouyal file Form 4?
Philippe Amouyal has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.); CAVA (CAVA GROUP, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.